Back to results
US 2023/0416681 A9Published application
Augmentation of Cell Therapy Efficacy Including Treatment with Alpha 1,3 Fucosyltransferase
AssigneeTargazyme, Inc.
InventorsStephen D. Wolpe, Leonard Miller, Lynnet Koh, Thomas E. Ichim
Life of this patent
Estimating the term…
Abstract
Disclosed are methods, compositions of matter, and kits useful for augmentation of cells through modification of cellular membrane properties following ex vivo treatment.
Claims20
A method of enhancing homing and engraftment of one or more T cells, the method comprising the step of:
- contacting a T cell population with α1,3-fucosyltransferase VI ex vivo to fucosylate at least one surface molecule on the T cell(s) to enhance selectin mediated binding thereof.
A method of enhancing homing and engraftment of one or more T cells, the method comprising the step of:
- contacting a T cell population with α1,3-fucosyltransferase VII ex vivo to fucosylate at least one surface molecule on the T cell(s) to enhance selectin mediated binding thereof.
A method, comprising the step of:
- administering an ex vivo expanded population of fucosylated T cells to a patient in need thereof, the population of cells being fucosylated by contact with α1,3-fucosyltransferase VI and/or α1,3-fucosyltransferase VII that fucosylated at least one surface molecule on the T cells to enhance selectin mediated binding thereof, and wherein at least one of:
- (a) the T cell population comprises regulatory T cells fucosylated by contact with α1,3-fucosyltransferase VI;
- and/or
- (b) the T cell population comprises cytotoxic T cells fucosylated by contact with α1,3-fucosyltransferase VII.
1 more element
A method of enhancing homing and engraftment of one or more endothelial progenitor cells, the method comprising the step of:
- contacting a cell population comprising one or more endothelial progenitor cells with an α1,3-fucosyltransferase ex vivo to enhance selectin mediated binding thereof.
Dependencies are inferred from the claim text.